Intranasal Flu Vaccine May Strengthen Mucosal Immunity

Why Could a Nasal Flu Vaccine Offer Different Immune Protection?

Most influenza vaccines are assessed largely by measuring antibody responses in the blood, especially hemagglutination inhibition antibodies. Those markers are useful, but they do not fully describe mucosal immunity in the nose, throat and respiratory tract. Intranasal live attenuated influenza vaccines are designed to mimic a limited upper-airway infection without causing typical flu illness in eligible people, which may help activate immune responses closer to the site of viral entry.

This distinction is clinically important because influenza transmission and early infection begin at mucosal surfaces. Local secretory antibodies, tissue-resident memory T cells and innate immune signaling may contribute to protection even when standard blood antibody measurements look modest. Researchers are increasingly arguing that vaccine performance should be evaluated with broader immune markers, particularly for respiratory viruses.

Who Is Eligible for the Intranasal Flu Vaccine?

The nasal spray flu vaccine used in the United States is a live attenuated influenza vaccine. CDC guidance lists it as an option for eligible people aged 2 through 49 years, while annual influenza vaccination is recommended for most people aged 6 months and older. Because it contains weakened live virus, it is not recommended for several groups, including pregnant people, some immunocompromised patients and certain children with asthma or recent wheezing.

For clinicians, the practical message is not that nasal vaccine should replace injectable flu vaccines for all patients. Instead, the renewed interest highlights that vaccine choice can be individualized. Needle-free delivery may also improve uptake for some patients, while injectable inactivated or recombinant vaccines remain the preferred or only appropriate choice for others.

How Could This Change Future Flu Vaccine Research?

If intranasal vaccination produces meaningful airway immunity, researchers may need to expand the endpoints used in influenza vaccine studies. Blood antibody titers remain valuable, but they may miss immune activity that affects infection risk, symptom duration or viral shedding. This is especially relevant for vaccines intended to reduce transmission, not only prevent hospitalization.

The broader implication extends beyond seasonal flu. COVID-19, RSV and other respiratory viruses have renewed interest in vaccines that generate protection at mucosal entry points. Better tools for measuring nasal antibodies, local T-cell memory and real-world transmission effects could help regulators and public health agencies compare respiratory vaccines more accurately.